Subtype
Urinary System Adenocarcinoma
CI-CAN-00004181Explore in graph →
378 active trials17 approved drugs60 evidence items
- NCIt
- C224634
Loading cancer entity…
Subtype
CI-CAN-00004181Explore in graph →
Clinical trials
1,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (279)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04764487 | A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line(AxiPRO) | unknown | Phase 3 | 178 | WepromOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT01481870 | Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma(CROSS-J-RCC) | unknown | Phase 3 | 120 | Yamagata UniversityOTHER | 1 |
| Feb 25, 2013 |
| clinicaltrials |
| NCT00869011 | Exercise for Patients With Renal Cell Cancer Receiving Sunitinib | unknown | Phase 3 | 70 | Charite University, Berlin, GermanyOTHER | 1 | Dec 23, 2009 | clinicaltrials |
Data updated 22 days agoSource updated May 3, 2022source: clinicaltrials